Finerenone, Eplerenone, and Spironolactone in HFpEF: A Bayesian Network Meta-Analysis of Efficacy and Safety

20260 citationsJournal Article

Authors

Vitor Bagattoli · Universidade para o Desenvolvimento do Alto Vale do Itajaí

Helena Schell dos Santos · Universidade para o Desenvolvimento do Alto Vale do Itajaí

Juliana Giorgi · Hospital Israelita Albert Einstein

P. K. A. Batista · Universidade Federal da Paraíba

Samantha Cristiane Lopes · Universidade para o Desenvolvimento do Alto Vale do Itajaí

M V Gambetta · Universidade para o Desenvolvimento do Alto Vale do Itajaí

Abstract

In HFpEF/HFmrEF, finerenone was the only MRA to significantly reduce hospitalization for HF, while no agent significantly reduced cardiovascular mortality and hyperkalemia risk increased across therapies. Overall, finerenone may offer the most favorable efficacy-safety balance among MRAs, pending confirmation in larger dedicated trials.

Topics & Keywords

Hormonal Regulation and Hypertension Heart Failure Treatment and Management Adrenal Hormones and Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Heart Failure

DOI: 10.1093/ejhf/xuag083

Field-Weighted Citation Impact: 0.00